4423.10 +73.05 (1.68%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
4332.05
Today’s High
4468.75
52 Week Low
3655.0
52 Week High
4645.55
4448.00 +98.45 (2.26%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
4360.25
Today’s High
4468.25
52 Week Low
3654
52 Week High
4645
Key Metrics
- Market Cap (In Cr) 72246.41
- Beta 0.23
- Div. Yield (%) 0.69
- P/B 3.76
- TTM P/E 19.3
- Peg Ratio 1.85
- Sector P/E 30.05
- D/E -
- Open Price 4332.05
- Prev Close 4350.05
Analysis
Price Analysis
-
1 Week0.48%
-
3 Months-3.03%
-
6 Month2.99%
-
YTD2.64%
-
1 Year-0.06%
Risk Meter
- 18% Low risk
- 18% Moderate risk
- 18% Balanced Risk
- 18% High risk
- 18% Extreme risk
Recos
40 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 1
- Sell
- 2
- Hold
- 6
- Buy
- 17
- Strong Buy
- 14
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 21545.2
- Selling/ General/ Admin Expenses Total
- 7339.9
- Depreciation/ Amortization
- 1165.2
- Total Operating Expense
- 18942.7
- Operating Income
- 2602.5
- Net Income Before Taxes
- 3061.4
- Net Income
- 2182.5
- Diluted Normalized EPS
- 165.95
- Period
- 2022
- Total Assets
- 29746.9
- Total Liabilities
- 10534.5
- Total Equity
- 19212.4
- Tangible Book Valueper Share Common Eq
- 961.93
- Period
- 2022
- Cashfrom Operating Activities
- 2810.8
- Cashfrom Investing Activities
- -2638.7
- Cashfrom Financing Activities
- -242.2
- Net Changein Cash
- 3.2
- Period
- 2021
- Total Revenue
- 19047.5
- Selling/ General/ Admin Expenses Total
- 6385.1
- Depreciation/ Amortization
- 1228.8
- Total Operating Expense
- 16402.2
- Operating Income
- 2645.3
- Net Income Before Taxes
- 2883.5
- Net Income
- 1951.6
- Diluted Normalized EPS
- 142.73
- Period
- 2021
- Total Assets
- 26616.8
- Total Liabilities
- 8975.1
- Total Equity
- 17641.7
- Tangible Book Valueper Share Common Eq
- 818.04
- Period
- 2021
- Cashfrom Operating Activities
- 3570.3
- Cashfrom Investing Activities
- -2266
- Cashfrom Financing Activities
- -29.8
- Net Changein Cash
- 1285.8
- Period
- 2020
- Total Revenue
- 17517
- Selling/ General/ Admin Expenses Total
- 5881
- Depreciation/ Amortization
- 1163.1
- Total Operating Expense
- 16203
- Operating Income
- 1314
- Net Income Before Taxes
- 1885.7
- Net Income
- 2026
- Diluted Normalized EPS
- 187.62
- Period
- 2020
- Total Assets
- 23225.3
- Total Liabilities
- 7626.5
- Total Equity
- 15598.8
- Tangible Book Valueper Share Common Eq
- 749.67
- Period
- 2020
- Cashfrom Operating Activities
- 2984.1
- Cashfrom Investing Activities
- -492.3
- Cashfrom Financing Activities
- -2515.9
- Net Changein Cash
- -26.6
- Period
- 2019
- Total Revenue
- 15448.2
- Selling/ General/ Admin Expenses Total
- 5839.9
- Depreciation/ Amortization
- 1134.8
- Total Operating Expense
- 13404.8
- Operating Income
- 2043.4
- Net Income Before Taxes
- 2292
- Net Income
- 1950
- Diluted Normalized EPS
- 111.64
- Period
- 2019
- Total Assets
- 22465.6
- Total Liabilities
- 8442
- Total Equity
- 14023.6
- Tangible Book Valueper Share Common Eq
- 559.81
- Period
- 2019
- Cashfrom Operating Activities
- 2870.4
- Cashfrom Investing Activities
- -772.7
- Cashfrom Financing Activities
- -2132.6
- Net Changein Cash
- -31.4
- Period
- 2018
- Total Revenue
- 14281
- Selling/ General/ Admin Expenses Total
- 5670.3
- Depreciation/ Amortization
- 1077.2
- Total Operating Expense
- 13007
- Operating Income
- 1274
- Net Income Before Taxes
- 1350.4
- Net Income
- 946.8
- Diluted Normalized EPS
- 64.61
- Period
- 2018
- Total Assets
- 22544.3
- Total Liabilities
- 9972.7
- Total Equity
- 12571.6
- Tangible Book Valueper Share Common Eq
- 474.6
- Period
- 2018
- Cashfrom Operating Activities
- 1803
- Cashfrom Investing Activities
- -1488.3
- Cashfrom Financing Activities
- -444
- Net Changein Cash
- -123.6
- Period
- 2017
- Total Revenue
- 14196.1
- Selling/ General/ Admin Expenses Total
- 5605.4
- Depreciation/ Amortization
- 1026.6
- Total Operating Expense
- 12743.4
- Operating Income
- 1452.7
- Net Income Before Taxes
- 1553.7
- Net Income
- 1292.1
- Diluted Normalized EPS
- 81.14
- Period
- 2017
- Total Assets
- 21816.5
- Total Liabilities
- 9554.4
- Total Equity
- 12262.1
- Tangible Book Valueper Share Common Eq
- 461.23
- Period
- 2017
- Cashfrom Operating Activities
- 2144.5
- Cashfrom Investing Activities
- -1840.4
- Cashfrom Financing Activities
- -369.2
- Net Changein Cash
- -114.3
- Period
- 2022-12-31
- Total Revenue
- 6789.8
- Selling/ General/ Admin Expenses Total
- 2836.5
- Depreciation/ Amortization
- 323.7
- Total Operating Expense
- 5175
- Operating Income
- 1614.8
- Net Income Before Taxes
- 1637.7
- Net Income
- 1243.9
- Diluted Normalized EPS
- 75.37
- Period
- 2022-12-31
- Period
- 2022-12-31
- Period
- 2022-09-30
- Total Revenue
- 6331.8
- Selling/ General/ Admin Expenses Total
- 2583.4
- Depreciation/ Amortization
- 309.2
- Total Operating Expense
- 4742.1
- Operating Income
- 1589.7
- Net Income Before Taxes
- 1613.6
- Net Income
- 1114.2
- Diluted Normalized EPS
- 67.08
- Period
- 2022-09-30
- Total Assets
- 29168.9
- Total Liabilities
- 8393.7
- Total Equity
- 20775.2
- Tangible Book Valueper Share Common Eq
- 1029.64
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 1593.6
- Cashfrom Investing Activities
- 81
- Cashfrom Financing Activities
- -2314.6
- Net Changein Cash
- -575.9
- Period
- 2022-06-30
- Total Revenue
- 5232.9
- Selling/ General/ Admin Expenses Total
- 2368.2
- Depreciation/ Amortization
- 301.8
- Total Operating Expense
- 4581.3
- Operating Income
- 651.6
- Net Income Before Taxes
- 1468
- Net Income
- 1189
- Diluted Normalized EPS
- 71.48
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 5474.9
- Selling/ General/ Admin Expenses Total
- 2384.2
- Depreciation/ Amortization
- 293
- Other Operating Expenses Total
- -6.7
- Total Operating Expense
- 5310.2
- Operating Income
- 164.7
- Net Income Before Taxes
- 258.9
- Net Income
- 97
- Diluted Normalized EPS
- 34.78
- Period
- 2022-03-31
- Total Assets
- 29746.9
- Total Liabilities
- 10534.5
- Total Equity
- 19212.4
- Tangible Book Valueper Share Common Eq
- 961.93
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 2810.8
- Cashfrom Investing Activities
- -2638.7
- Cashfrom Financing Activities
- -242.2
- Net Changein Cash
- 3.2
- Period
- 2021-12-31
- Total Revenue
- 5338.3
- Selling/ General/ Admin Expenses Total
- 2303.2
- Depreciation/ Amortization
- 294.2
- Total Operating Expense
- 4416.8
- Operating Income
- 921.5
- Net Income Before Taxes
- 974.2
- Net Income
- 709.3
- Diluted Normalized EPS
- 42.86
- Period
- 2021-12-31
- Period
- 2021-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day4346.78
- 10 Day4319.88
- 20 Day4317.91
- 50 Day4347.58
- 100 Day4350.96
- 300 Day4294.35
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Cipla
- 1028.15
- -1.6
- -0.16
- 1185.2
- 880
- 82514.33
- Divis Laboratories
- 2770.5
- -7.65
- -0.28
- 4640.95
- 2745.1
- 76570.43
- Dr Reddys Laboratories
- 4423.1
- 73.05
- 1.68
- 4645.55
- 3655
- 72392.58
- Torrent Pharmaceuticals
- 1530.6
- -9.2
- -0.6
- 1722.7
- 1235.88
- 51846.46
- Abbott India
- 20699.95
- -181.4
- -0.87
- 22481.8
- 15426.74
- 44352.08
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Cipla
- 30.72
- 3.96
- 11.75
- 10.53
- Divis Laboratories
- 25.85
- 6.53
- 22.49
- 28.33
- Dr Reddys Laboratories
- 26.26
- 3.76
- 12.1
- 10.32
- Torrent Pharmaceuticals
- 47.8
- 8.71
- 16.36
- 10.81
- Abbott India
- 55.53
- 15.73
- 27.07
- 14.45
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 73.05%
- 121,639,750
- FIRST SENTIER INVESTORS ICVC - STEWART INVESTORS ASIA PACIFIC LEADERS SUSTAINABILITY FUND
- 2.2%
- 3,658,520
- GOVERNMENT OF SINGAPORE
- 1.36%
- 2,267,409
- GOVERNMENT PENSION FUND GLOBAL
- 1.06%
- 1,760,157
- Others
- 22.06%
- 36,750,728
- LIFE INSURANCE CORPORATION OF INDIA P & GS FUND
- 8.95%
- 14,896,920
- HDFC LIFE INSURANCE COMPANY LIMITED
- 1.03%
- 1,718,739
- Others
- 2.24%
- 3,741,167
- SBI-ETF NIFTY 50
- 1.57%
- 2,618,721
- HDFC TRUSTEE COMPANY LTD. A/C HDFC NIFTY 50 ETF
- 1.36%
- 2,266,282
- NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA ETF NIFTY 100
- 1.16%
- 1,938,128
- ICICI PRUDENTIAL SENSEX INDEX FUND
- 1.05%
- 1,744,834
- Others
- 5.79%
- 9,649,046
- J P Morgan Chase Bank NA
- 10.53%
- 17,536,620
- Others
- 7.73%
- 12,876,737
- Trusts
- 1.89%
- 3,151,513
- NPS TRUST-A/C HDFC PENSION MANAGEMENT COMPANY LTD SCHEME TAX SAVER- TIER 2
- 1.89%
- 3,139,887
- Unclaimed or Suspense or Escrow Account
- 0.21%
- 346,039
- HUF
- 0.17%
- 283,421
- Clearing Members
- 0.07%
- 113,492
- Others
- 0.92%
- 1,535,242
- Others
- 0.61%
- 1,007,547
- Others
- 0.49%
- 823,453
- Others
- 0.19%
- 323,017
- Others
- 0.14%
- 230,305
- Others
- 0.11%
- 181,982
- Others
- 0.1%
- 174,771
- Others
- 0.03%
- 42,166
- Others
- 0%
- 2,394
- Others
- 0%
- 400
- Non Promoter - Non Public shareholder
- 0.25%
- 422,761
- Others
- 0.25%
- 422,761
- Promoter & Promoter Group Shareholding
- 26.7%
- 44,461,128
- APS Trust (Trustees: G. V. Prasad and Satish Reddy Kallam)
- 20.62%
- 34,345,308
- KALLAM SATISH REDDY HUF (KALLAM SATISH REDDY)
- 3.32%
- 5,523,677
- GUNUPATI VENKATESWARA PRASAD HUF (GUNUPATI VENKATESWARA PRASAD)
- 1.53%
- 2,543,418
- SAMRAJYAM REDDY KALLAM
- 0.67%
- 1,120,499
- SATISH REDDY KALLAM
- 0.54%
- 901,002
- ANURADHA GUNUPATI
- 0.01%
- 9,205
- DEEPTI REDDY KALLAM
- 0%
- 5,140
- G VANI SANJANA REDDY
- 0%
- 5,140
- GUNUPATI MALLIKA REDDY
- 0%
- 5,139
- SHARATHCHANDRA REDDY GUNUPATI
- 0%
- 2,600
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 25-Jan-23
- Quarterly Results
- 28-Oct-22
- Quarterly Results
- 28-Jul-22
- Quarterly Results
- 19-May-22
- Audited Results & Final Dividend
- 28-Jan-22
- Quarterly Results
- 29-Oct-21
- Quarterly Results
- 27-Jul-21
- Quarterly Results
- 14-May-21
- Audited Results & Final Dividend
- 29-Jan-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 29-Jul-22
- 20-May-22
- AGM
- 29-Mar-22
- 25-Feb-22
- POM
- 28-Jul-21
- 20-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 19-May-22
- -
- 11-Jul-22
- 30
- 14-May-21
- -
- 09-Jul-21
- 25
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Dr Reddys Laboratories
- Industry Biotechnology & Drugs
- ISIN INE089A01023
- BSE Code 500124
- NSE Code DRREDDY
Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.
MANAGEMENT
- K. Satish Reddy Chairman of the Board
- G. V. Prasad Co-Chairman of the Board, Managing Director
- Erez Israeli Chief Executive Officer
- Parag Agarwal Chief Financial Officer
- Patrick Aghanian Chief Executive Officer, European Generics
- Marc Kikuchi Chief Executive Officer, North America Generics
- M. Ramana Chief Executive Officer, Branded Markets (India and Emerging Markets)
- Deepak Sapra Chief Executive Officer, API and Services
- Archana Bhaskar Chief Human Resource Officer
- Mukesh Rathi Chief Digital and Information Officer
Company Summary
DR REDDYS LABORATORIES SUMMARY
Dr Reddys Laboratories is trading 1.68% upper at Rs 4423.10 as compared to its last closing price. Dr Reddys Laboratories has been trading in the price range of 4468.75 & 4332.05. Dr Reddys Laboratories has given 2.64% in this year & 0.48% in the last 5 days.
Dr Reddys Laboratories has TTM P/E ratio 19.3 as compared to the sector P/E of 30.05. There are 40 analysts who have initiated coverage on Dr Reddys Laboratories. There are 14 analysts who have given it a strong buy rating & 17 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.
The company posted a net profit of 1243.9 Crores in its last quarter.
Listed peers of Dr Reddys Laboratories include Cipla (-0.16%), Divis Laboratories (-0.28%), Dr Reddys Laboratories (1.68%) etc.
Dr Reddys Laboratories has a 26.7% promoter holding & 0.25% public holding.
FAQs about Dr Reddys Laboratories
Dr Reddys Laboratories is trading at 4423.10 as on 7 Feb, 2023 10:25:39 AM. This is 1.68% upper as compared to its previous closing price of 4350.05
The market capitalization of Dr Reddys Laboratories is 72246.41 Cr as on 7 Feb, 2023 10:25:39 AM.
The average broker rating on Dr Reddys Laboratories is Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong sell rating
- 2 analysts have given a sell rating
- 6 analysts have given a hold rating
- 17 analysts have given a buy rating
- 14 analysts have given a strong buy rating
The 52 wk high for Dr Reddys Laboratories is 4645.55 whereas the 52 wk low is 3655.0
Dr Reddys Laboratories can be analyzed on the following key metrics -
- TTM P/E: 19.3
- Sector P/E: 30.05
- Dividend Yield: 0.69%
- D/E ratio: -
Dr Reddys Laboratories reported a net profit of 2182.5 Cr in 2022.
